Shares of ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) have earned a consensus broker rating score of 1.50 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and three have issued a strong buy recommendation on the company.
Brokers have set a 1-year consensus price target of $12.00 for the company and are forecasting that the company will post ($0.34) EPS for the current quarter, according to Zacks. Zacks has also assigned ASLAN PHARMACEUTICALS ADR REP 5 an industry rank of 80 out of 255 based on the ratings given to related companies.
Several analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of ASLAN PHARMACEUTICALS ADR REP 5 in a research note on Tuesday, July 3rd. Zacks Investment Research upgraded shares of ASLAN PHARMACEUTICALS ADR REP 5 from a “sell” rating to a “hold” rating in a research note on Friday, October 5th.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. MYDA Advisors LLC acquired a new position in ASLAN PHARMACEUTICALS ADR REP 5 during the second quarter worth about $195,000. Platinum Investment Management Ltd. acquired a new position in ASLAN PHARMACEUTICALS ADR REP 5 during the second quarter worth about $2,532,000. Finally, Temasek Holdings Private Ltd purchased a new stake in shares of ASLAN PHARMACEUTICALS ADR REP 5 during the second quarter worth about $12,660,000. Institutional investors own 10.93% of the company’s stock.
Shares of NASDAQ ASLN opened at $7.30 on Friday. ASLAN PHARMACEUTICALS ADR REP 5 has a 52 week low of $5.08 and a 52 week high of $10.44.
ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) last announced its quarterly earnings data on Monday, August 6th. The company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.06). As a group, equities analysts forecast that ASLAN PHARMACEUTICALS ADR REP 5 will post -1.34 EPS for the current fiscal year.
ASLAN PHARMACEUTICALS ADR REP 5 Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, develops therapeutics for the treatment cancer in Asia, the United States, Europe, and internationally. The company's product pipeline includes Varlitinib, a novel agent, which has completed Phase II studies in gastric and breast cancer, and entered into pivotal studies for biliary tract cancer; ASLAN002, a potent cMET and Recepteur d'Origine Nantais (RON) inhibitor that is in Phase II development for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase I clinical trials to treat acute myeloid leukemia and solid tumors.
Read More: Diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ASLAN PHARMACEUTICALS ADR REP 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEUTICALS ADR REP 5 and related companies with MarketBeat.com's FREE daily email newsletter.